{"transactions":[{"id":3006044,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-15T16:15:09.000Z","date":"2020-10-14","kind":"other","acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 14, 2020, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 400,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 14, 2020, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 400,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by the Canaan Fund.  Canaan IX is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3589554,"source":{"system":"sec-edgar","filing":"0000899243-20-028308","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924320028308/doc4.xml","form_type":"4"}},{"id":3078551,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-21T16:10:28.000Z","date":"2020-07-20","kind":"other","acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 20, 2020, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 500,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 20, 2020, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 500,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by the Canaan Fund.  Canaan IX is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3989554,"source":{"system":"sec-edgar","filing":"0000899243-20-019796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924320019796/doc4.xml","form_type":"4"}},{"id":3309197,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-16T16:24:24.000Z","date":"2020-01-14","kind":"other","acquired":false,"shares":881000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 14, 2020, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 881,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 14, 2020, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 881,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by the Canaan Fund.  The sole general partner of the Canaan Fund is Canaan IX, and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":7925919,"source":{"system":"sec-edgar","filing":"0000899243-20-001324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924320001324/doc4.xml","form_type":"4"}},{"id":3470393,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Preferred Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":false,"shares":427020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":213510},"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470392,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Preferred Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":false,"shares":654298,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":327149},"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470391,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":false,"shares":1790580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":895290},"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470390,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":false,"shares":4120823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2060411},"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470389,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":false,"shares":2214825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1107412},"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470388,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":false,"shares":7398272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3699136},"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470387,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":true,"shares":213510,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":8806919,"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470386,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":true,"shares":327149,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":8593409,"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470385,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":true,"shares":895290,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":8266260,"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470384,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":true,"shares":2060411,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":7370970,"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470383,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":true,"shares":1107412,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":5310559,"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3470382,"issuer":{"id":4817,"kind":"organization","name":"TheRealReal, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-02T16:35:40.000Z","date":"2019-07-02","kind":"exercise","acquired":true,"shares":3699136,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series G Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one-half of one share of the Issuer's Common Stock (\"Shares\") immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan IX, collectively.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":4203147,"source":{"system":"sec-edgar","filing":"0000899243-19-018885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319018885/doc4.xml","form_type":"4"}},{"id":3492312,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-12T16:11:53.000Z","date":"2019-06-10","kind":"other","acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 10, 2019, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 500,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 10, 2019, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 500,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by the Canaan Fund.  Canaan IX is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":4489554,"source":{"system":"sec-edgar","filing":"0000899243-19-016634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924319016634/doc4.xml","form_type":"4"}},{"id":3797905,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-03T17:45:24.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":2209833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 1, 2018, the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration.  The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2018, the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration.  The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 1, 2018, the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration.  The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\", and together with the Canaan Fund, the \"Canaan Entities\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":679948},"source":{"system":"sec-edgar","filing":"0000899243-18-026089","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924318026089/doc4.xml","form_type":"4"}},{"id":3797904,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-03T17:45:24.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":4462837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 1, 2018, the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration.  The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2018, the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration.  The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 1, 2018, the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration.  The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\", and together with the Canaan Fund, the \"Canaan Entities\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1373180},"source":{"system":"sec-edgar","filing":"0000899243-18-026089","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924318026089/doc4.xml","form_type":"4"}},{"id":3797903,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-10-03T17:45:24.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":9543387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 1, 2018, the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration.  The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2018, the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration.  The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 1, 2018, the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration.  The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\", and together with the Canaan Fund, the \"Canaan Entities\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2936426},"source":{"system":"sec-edgar","filing":"0000899243-18-026089","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924318026089/doc4.xml","form_type":"4"}},{"id":3797902,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T17:45:24.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":4989554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 1, 2018, the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration.  The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners IX LLC (\"Canaan IX\", and together with the Canaan Fund, the \"Canaan Entities\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":4989554,"source":{"system":"sec-edgar","filing":"0000899243-18-026089","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538676/000089924318026089/doc4.xml","form_type":"4"}},{"id":4370064,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-28T17:36:15.000Z","date":"2017-03-27","kind":"other","acquired":false,"shares":750000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2017, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 750,000 shares of Common Stock of the issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 27, 2017, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 750,000 shares of Common Stock of the issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by the Canaan Fund.  Canaan IX, is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2494381,"source":{"system":"sec-edgar","filing":"0000899243-17-008751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924317008751/doc4.xml","form_type":"4"}},{"id":4536771,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-01T19:27:12.000Z","date":"2016-11-30","kind":"other","acquired":false,"shares":400000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On November 30, 2016, the Canaan Fund distributed, for no consideration, 400,000 shares of Common Stock of the issuer (the \"Shares\") to its limited partners and to Canaan IX, its general partner, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On November 30, 2016, the Canaan Fund distributed, for no consideration, 400,000 shares of Common Stock of the issuer (the \"Shares\") to its limited partners and to Canaan IX, its general partner, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3244381,"source":{"system":"sec-edgar","filing":"0000899243-16-034627","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316034627/doc4.xml","form_type":"4"}},{"id":4536770,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-01T19:27:12.000Z","date":"2016-11-29","kind":"sale","acquired":false,"shares":22086,"price":11.1839,"value":247007.6154,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.06 - $11.37, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3644381,"source":{"system":"sec-edgar","filing":"0000899243-16-034627","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316034627/doc4.xml","form_type":"4"}},{"id":4540857,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-28T22:10:00.000Z","date":"2016-11-28","kind":"sale","acquired":false,"shares":20840,"price":11.3312,"value":236142.208,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.11 - $11.69, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3666467,"source":{"system":"sec-edgar","filing":"0000899243-16-034442","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316034442/doc4.xml","form_type":"4"}},{"id":4540856,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-28T22:10:00.000Z","date":"2016-11-25","kind":"sale","acquired":false,"shares":6729,"price":11.7909,"value":79340.9661,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.67 - $12.07, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3687307,"source":{"system":"sec-edgar","filing":"0000899243-16-034442","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316034442/doc4.xml","form_type":"4"}},{"id":4540855,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-28T22:10:00.000Z","date":"2016-11-23","kind":"sale","acquired":false,"shares":10890,"price":11.8385,"value":128921.265,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.3950 - $12.05, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3694036,"source":{"system":"sec-edgar","filing":"0000899243-16-034442","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316034442/doc4.xml","form_type":"4"}},{"id":4544615,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-22T23:48:40.000Z","date":"2016-11-22","kind":"sale","acquired":false,"shares":42550,"price":11.7057,"value":498077.535,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.56 - $11.90, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3704926,"source":{"system":"sec-edgar","filing":"0000899243-16-034194","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316034194/doc4.xml","form_type":"4"}},{"id":4546843,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-21T23:48:24.000Z","date":"2016-11-21","kind":"sale","acquired":false,"shares":13548,"price":11.7202,"value":158785.2696,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.55 - $11.835, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3747476,"source":{"system":"sec-edgar","filing":"0000899243-16-034052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316034052/doc4.xml","form_type":"4"}},{"id":4546842,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-21T23:48:24.000Z","date":"2016-11-18","kind":"sale","acquired":false,"shares":12805,"price":11.6427,"value":149084.7735,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.48 - $11.73, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3761024,"source":{"system":"sec-edgar","filing":"0000899243-16-034052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316034052/doc4.xml","form_type":"4"}},{"id":4546841,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-21T23:48:24.000Z","date":"2016-11-17","kind":"sale","acquired":false,"shares":18971,"price":11.5027,"value":218217.7217,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.02 - $11.70, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3773829,"source":{"system":"sec-edgar","filing":"0000899243-16-034052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316034052/doc4.xml","form_type":"4"}},{"id":4552402,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-17T00:13:07.000Z","date":"2016-11-16","kind":"sale","acquired":false,"shares":18517,"price":11.5544,"value":213952.8248,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.24 - $11.85, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3792800,"source":{"system":"sec-edgar","filing":"0000899243-16-033704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316033704/doc4.xml","form_type":"4"}},{"id":4552401,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-17T00:13:07.000Z","date":"2016-11-15","kind":"sale","acquired":false,"shares":33064,"price":11.477,"value":379475.528,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.23 - $11.60, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3811317,"source":{"system":"sec-edgar","filing":"0000899243-16-033704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316033704/doc4.xml","form_type":"4"}},{"id":4557256,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-14T21:41:22.000Z","date":"2016-11-14","kind":"sale","acquired":false,"shares":23744,"price":11.2052,"value":266056.2688,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.00 - $11.37, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3844381,"source":{"system":"sec-edgar","filing":"0000899243-16-033335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316033335/doc4.xml","form_type":"4"}},{"id":4557255,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-14T21:41:22.000Z","date":"2016-11-11","kind":"sale","acquired":false,"shares":35391,"price":11.2023,"value":396460.5993,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.00 - $11.44, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3868125,"source":{"system":"sec-edgar","filing":"0000899243-16-033335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316033335/doc4.xml","form_type":"4"}},{"id":4557254,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-14T21:41:22.000Z","date":"2016-11-10","kind":"sale","acquired":false,"shares":27135,"price":11.0702,"value":300389.877,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.00 - $11.24, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3903516,"source":{"system":"sec-edgar","filing":"0000899243-16-033335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316033335/doc4.xml","form_type":"4"}},{"id":4560367,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-10T21:36:12.000Z","date":"2016-11-09","kind":"sale","acquired":false,"shares":13730,"price":11.0341,"value":151498.193,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.00 - $11.15, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Canaan IX L.P. (the \"Canaan Fund\").  Canaan Partners IX LLC (\"Canaan IX\" and together with the Canaan Fund, the \"Canaan Entities\") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3930651,"source":{"system":"sec-edgar","filing":"0000899243-16-033178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316033178/doc4.xml","form_type":"4"}},{"id":4580584,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":145934,"kind":"organization","name":"Canaan IX L.P.","position":1,"cik":"0001538676","reported_name":"Canaan IX L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104578,"kind":"organization","name":"Canaan Partners IX LLC","position":2,"cik":"0001654586","reported_name":"Canaan Partners IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-10-12T19:27:42.000Z","date":"2016-10-11","kind":"other","acquired":false,"shares":300000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 11, 2016, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 300,000 shares of Common Stock of the issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 11, 2016, Canaan IX L.P. (the \"Canaan Fund\") distributed, for no consideration, 300,000 shares of Common Stock of the issuer (the \"Shares\") to its limited partners and to Canaan Partners IX LLC (\"Canaan IX\" and, together with the Canaan Fund, the \"Canaan Entities\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by the Canaan Fund.  Canaan IX, is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors.  Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3944381,"source":{"system":"sec-edgar","filing":"0000899243-16-031602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000089924316031602/doc4.xml","form_type":"4"}}]}